Back to resultsOmega-3 Fatty Acids For Treatment Of Young Children With Autism (OMG)
Primary Purpose
Autism Spectrum Disorder
Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Omega-3 Fatty Acids
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Autism Spectrum Disorder focused on measuring Autism Spectrum Disorder, Clinical Trial, Omega-3 Fatty Acids, Toddlers
Eligibility Criteria
Inclusion Criteria:
- Male or female outpatients 2-5 years of age.
- Meet Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV) criteria. DSM-IV criteria for an autism spectrum disorder, (Autistic disorder, Asperger syndrome or PDD-NOS) will be established by a clinician with expertise with individuals with ASD based on parent interview, Autism Diagnostic Observation Schedule (ADO) and Autism Diagnostic Interview (ADI-R)
- If already receiving stable non pharmacologic educational, behavioral, dietary and or/ natural health product interventions during the preceding 3 months prior to Screening, will not electively initiate new or modify ongoing interventions for the duration of the study unless the child's condition is worsening or their turn comes up on the treatment waiting list.
- Have normal physical examination and laboratory test results at Screening. If abnormal, the finding(s) must be deemed clinically insignificant by the Investigator.
- The parents must be able to speak and understand English sufficiently to allow for the completion of all study assessments.
Exclusion Criteria:
- Patients born prior to 35 weeks gestational age.
- Patients with any primary psychiatric diagnosis other than autism at Screening. We are aware the most primary psychiatric disorders are unlikely to be diagnosed in this age group
- Patients with a medical history of neurological disease, including, but not limited to, epilepsy/seizure disorder (except simple febrile seizures), movement disorder, tuberous sclerosis, fragile X, and any other known genetic syndromes, or known abnormal MRI/structural lesion of the brain.
- Patients with a medical condition that might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being. Patients with evidence or history of malignancy or any significant hematological, endocrine, cardiovascular (including any rhythm disorder), respiratory, renal, hepatic, or gastrointestinal disease, or coagulation deficits.
- Patients taking psychoactive medication(s) (e.g.,stimulants, antidepressants, antipsychotics, antiepileptics, anxiolytics, clonidine).
- Patients that have been off pharmacotherapy for less than 6 weeks.
- Patients who are participating in another clinical trial
- Patients on anticoagulants
- Patients who know that they will initiate or change nonpharmacologic interventions during the course of the study.
- Patients unable to tolerate venipuncture procedures for blood sampling.
- Patients taking Omega-3 supplements who have not discontinued treatment for six weeks prior to entering into the study.
- Patients who have allergies to any of the ingredients in omega-3 (study product) or the placebo.
Sites / Locations
- Holland Bloorview Kids Rehabilitation Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Omega-3 Fatty Acids
Placebo
Arm Description
Children will be administered 3.75ml of the liquid formulation of Nutra Sea high-EPA (HP) (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2.
Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2.
Outcomes
Primary Outcome Measures
Change From Baseline in the Pervasive Developmental Disorder-Behavioral Inventory (PDDBI) - Autism Composite Score
The PDDBI measures autism symptomology. The autism composite score was used as the primary outcome measure for autism symptom severity.
PDDBI Autism Composite Scale Range:
Minimum Range = 10 (lower autism symptom severity) Maximum Range = 100 (higher autism symptom severity)
The Autism Composite is calculated from the sum of T-scores of the Sensory/Perceptual Approach Behaviours, Ritualisms/Resistance to Change, Social Pragmatic Problems, and Semantic/Pragmatic Problems domains subtracted by the sum of T-scores of the Social Approach Behaviours, and Expressive Language domain then converted into the Autism Composite as a T-score.
Mean change between baseline and week 24 is reported. A negative change indicates improvement
Change From Baseline in the Behaviour Assessment System for Children (BASC-2) - Externalizing Problems Composite
The BASC-2 externalizing problems composite measures hyperactivity and aggressive behaviours.
Primary Outcome domain: Externalizing Problems composite
Externalizing Problems Composite T-Score Range:
Minimum Range: 10 (lower externalizing problems) Maximum Range: 120 (higher externalizing problems)
The Externalizing Problems composite is computed from the sum of t-scores from the hyperactivity and aggression subscales then converted into the externalizing problems composite t-score.
Mean change between baseline and week 24 is reported. A negative change indicates improvement.
Secondary Outcome Measures
Number of Participants Classified as Responders by the Clinical Global Impression - Improvement (CGI-I)
The CGI-I is a seven-point scale that provides a clinician rating of global improvement and as such is already inherently a measure of change. It requires the clinician to assess the degree to which the participant's illness has improved or worsened relative to a baseline state before the intervention.
Change is rated as:
0- Not assessed
Very Much Improved
Much Improved
Minimally Improved
No Change
Minimally Worse
Much Worse
Very Much Worse
Participants are classified as responders if their CGI-I score was 1 or 2 and non-responders for CGI-I scores of 3 to 7.
Change From Baseline in the Vineland Adaptive Behavioral Scales (VABS) - Adaptive Functioning Composite
The VABS is a measure of adaptive behavior in daily settings. Secondary measure domain: The adaptive functioning composite describes an individuals overall functioning
Adaptive Behaviour Composite Standard Score Range:
Minimum range: 20 (low adaptive functioning) Maximum range: 160 (high adaptive functioning)
The adaptive behaviour composite standard score is computed from the sum of standard scores from the communication, daily living skills, socialization and motor skills domains and converted into the adaptive behavior composite standard score.
Change in the adaptive behaviour composite standard score from baseline to week 24 is reported. Positive change indicates improvement.
Change From Baseline in the Preschool Language Scale (PLS-4) - Total Language
The PLS-4 is a language measure that provides a global assessment of a child's language functioning abilities, receptive and expressive language.
Secondary outcome measure domain: Total language standard score
Total Language Standard Score Range:
Minimum range: 50 (lower language abilities) Maximum range: 150 (higher language abilities)
The total language standard score is computed from a sum of the auditory comprehension and expressive communication standard scores, then converted into the total language standard score.
Change of total language standard scores from baseline to week 24 is reported. Positive change indicates improvement
Full Information
NCT ID
NCT01248728
First Posted
November 22, 2010
Last Updated
April 12, 2016
Sponsor
Evdokia Anagnostou
Collaborators
Holland Bloorview Kids Rehabilitation Hospital, The Hospital for Sick Children
1. Study Identification
Unique Protocol Identification Number
NCT01248728
Brief Title
Omega-3 Fatty Acids For Treatment Of Young Children With Autism (OMG)
Official Title
A Randomized, Placebo-Controlled Trial of Omega-3 Fatty Acids in the Treatment of Young Children With Autism
Study Type
Interventional
2. Study Status
Record Verification Date
April 2016
Overall Recruitment Status
Completed
Study Start Date
November 2010 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
June 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Evdokia Anagnostou
Collaborators
Holland Bloorview Kids Rehabilitation Hospital, The Hospital for Sick Children
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a pilot, randomized, placebo-controlled trial of omega-3 fatty acids in autism. Autism, originally described by Kanner in 1943, is among the most severe of neurodevelopmental disorders. It is a Pervasive Developmental Disorder (PDD) affecting social and communicative functions and is also characterized by repetitive behaviors/restricted interests. It is also frequently accompanied by significant aggression, self-injury, irritability and hyperactivity, making care for these individuals an even greater challenge for families or institutional settings. Autism severely impacts the affected individual and family members, causing life-long functional impairment. In this protocol the investigators will use the terms "autism" and "autism spectrum disorder (ASD)" interchangeably to refer to Autistic disorder, Asperger Syndrome and PDD-Not Otherwise Specified (NOS).
Detailed Description
Currently risperidone is the only medication approved the by Food and Drug Administration (FDA) for this disorder, and specifically for irritability associated with autism, although not all patients with autism respond to risperidone. No pharmacologic treatments have been approved for use in preschool children, although it is clear that early intervention is associated with improved outcomes. Behavioral and educational therapies play a significant role in the management of autistic symptoms. The history of alternative treatments in autism is notable for the exaggerated benefit of a variety of supplements, such as high dose vitamins (e.g. B6, magnesium), and secretin. The current widespread use of alternative/nutritional supplements to patients with autism without scientifically demonstrated efficacy, underscores the necessity for scientifically sound studies to be conducted. Complementary and alternative medical therapies (CAM) are commonly employed by families of autistic children. Recent surveys have estimated the prevalence of such use to be between 30% and 95% (1,2,3). Omega-3 fatty acids were reported to be used in 28.7% of patients (1). However, only two small case series and a very small randomized study have been reported in this population to date. The investigators propose to conduct a randomized controlled trial of omega-3 fatty acids in preschoolers with ASD.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Autism Spectrum Disorder
Keywords
Autism Spectrum Disorder, Clinical Trial, Omega-3 Fatty Acids, Toddlers
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
38 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Omega-3 Fatty Acids
Arm Type
Active Comparator
Arm Description
Children will be administered 3.75ml of the liquid formulation of Nutra Sea high-EPA (HP) (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2.
Intervention Type
Dietary Supplement
Intervention Name(s)
Omega-3 Fatty Acids
Other Intervention Name(s)
Nutra Sea HP
Intervention Description
Children will be administered 3.75ml of the liquid formulation of Nutra Sea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Other Intervention Name(s)
Placebo Comparator
Intervention Description
Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
Primary Outcome Measure Information:
Title
Change From Baseline in the Pervasive Developmental Disorder-Behavioral Inventory (PDDBI) - Autism Composite Score
Description
The PDDBI measures autism symptomology. The autism composite score was used as the primary outcome measure for autism symptom severity.
PDDBI Autism Composite Scale Range:
Minimum Range = 10 (lower autism symptom severity) Maximum Range = 100 (higher autism symptom severity)
The Autism Composite is calculated from the sum of T-scores of the Sensory/Perceptual Approach Behaviours, Ritualisms/Resistance to Change, Social Pragmatic Problems, and Semantic/Pragmatic Problems domains subtracted by the sum of T-scores of the Social Approach Behaviours, and Expressive Language domain then converted into the Autism Composite as a T-score.
Mean change between baseline and week 24 is reported. A negative change indicates improvement
Time Frame
Baseline and 24 Weeks
Title
Change From Baseline in the Behaviour Assessment System for Children (BASC-2) - Externalizing Problems Composite
Description
The BASC-2 externalizing problems composite measures hyperactivity and aggressive behaviours.
Primary Outcome domain: Externalizing Problems composite
Externalizing Problems Composite T-Score Range:
Minimum Range: 10 (lower externalizing problems) Maximum Range: 120 (higher externalizing problems)
The Externalizing Problems composite is computed from the sum of t-scores from the hyperactivity and aggression subscales then converted into the externalizing problems composite t-score.
Mean change between baseline and week 24 is reported. A negative change indicates improvement.
Time Frame
Baseline and 24 Weeks
Secondary Outcome Measure Information:
Title
Number of Participants Classified as Responders by the Clinical Global Impression - Improvement (CGI-I)
Description
The CGI-I is a seven-point scale that provides a clinician rating of global improvement and as such is already inherently a measure of change. It requires the clinician to assess the degree to which the participant's illness has improved or worsened relative to a baseline state before the intervention.
Change is rated as:
0- Not assessed
Very Much Improved
Much Improved
Minimally Improved
No Change
Minimally Worse
Much Worse
Very Much Worse
Participants are classified as responders if their CGI-I score was 1 or 2 and non-responders for CGI-I scores of 3 to 7.
Time Frame
24 weeks
Title
Change From Baseline in the Vineland Adaptive Behavioral Scales (VABS) - Adaptive Functioning Composite
Description
The VABS is a measure of adaptive behavior in daily settings. Secondary measure domain: The adaptive functioning composite describes an individuals overall functioning
Adaptive Behaviour Composite Standard Score Range:
Minimum range: 20 (low adaptive functioning) Maximum range: 160 (high adaptive functioning)
The adaptive behaviour composite standard score is computed from the sum of standard scores from the communication, daily living skills, socialization and motor skills domains and converted into the adaptive behavior composite standard score.
Change in the adaptive behaviour composite standard score from baseline to week 24 is reported. Positive change indicates improvement.
Time Frame
Baseline and 24 Weeks
Title
Change From Baseline in the Preschool Language Scale (PLS-4) - Total Language
Description
The PLS-4 is a language measure that provides a global assessment of a child's language functioning abilities, receptive and expressive language.
Secondary outcome measure domain: Total language standard score
Total Language Standard Score Range:
Minimum range: 50 (lower language abilities) Maximum range: 150 (higher language abilities)
The total language standard score is computed from a sum of the auditory comprehension and expressive communication standard scores, then converted into the total language standard score.
Change of total language standard scores from baseline to week 24 is reported. Positive change indicates improvement
Time Frame
Baseline and 24 Weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female outpatients 2-5 years of age.
Meet Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV) criteria. DSM-IV criteria for an autism spectrum disorder, (Autistic disorder, Asperger syndrome or PDD-NOS) will be established by a clinician with expertise with individuals with ASD based on parent interview, Autism Diagnostic Observation Schedule (ADO) and Autism Diagnostic Interview (ADI-R)
If already receiving stable non pharmacologic educational, behavioral, dietary and or/ natural health product interventions during the preceding 3 months prior to Screening, will not electively initiate new or modify ongoing interventions for the duration of the study unless the child's condition is worsening or their turn comes up on the treatment waiting list.
Have normal physical examination and laboratory test results at Screening. If abnormal, the finding(s) must be deemed clinically insignificant by the Investigator.
The parents must be able to speak and understand English sufficiently to allow for the completion of all study assessments.
Exclusion Criteria:
Patients born prior to 35 weeks gestational age.
Patients with any primary psychiatric diagnosis other than autism at Screening. We are aware the most primary psychiatric disorders are unlikely to be diagnosed in this age group
Patients with a medical history of neurological disease, including, but not limited to, epilepsy/seizure disorder (except simple febrile seizures), movement disorder, tuberous sclerosis, fragile X, and any other known genetic syndromes, or known abnormal MRI/structural lesion of the brain.
Patients with a medical condition that might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being. Patients with evidence or history of malignancy or any significant hematological, endocrine, cardiovascular (including any rhythm disorder), respiratory, renal, hepatic, or gastrointestinal disease, or coagulation deficits.
Patients taking psychoactive medication(s) (e.g.,stimulants, antidepressants, antipsychotics, antiepileptics, anxiolytics, clonidine).
Patients that have been off pharmacotherapy for less than 6 weeks.
Patients who are participating in another clinical trial
Patients on anticoagulants
Patients who know that they will initiate or change nonpharmacologic interventions during the course of the study.
Patients unable to tolerate venipuncture procedures for blood sampling.
Patients taking Omega-3 supplements who have not discontinued treatment for six weeks prior to entering into the study.
Patients who have allergies to any of the ingredients in omega-3 (study product) or the placebo.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Evdokia Anagnostou, M.D.
Organizational Affiliation
Holland Bloorview Kids Rehabilitation Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Holland Bloorview Kids Rehabilitation Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4G 1R8
Country
Canada
12. IPD Sharing Statement
Citations:
PubMed Identifier
25798215
Citation
Mankad D, Dupuis A, Smile S, Roberts W, Brian J, Lui T, Genore L, Zaghloul D, Iaboni A, Marcon PM, Anagnostou E. A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism. Mol Autism. 2015 Mar 21;6:18. doi: 10.1186/s13229-015-0010-7. eCollection 2015.
Results Reference
derived
Learn more about this trial
Omega-3 Fatty Acids For Treatment Of Young Children With Autism (OMG)
We'll reach out to this number within 24 hrs